急性冠脉综合征长期丹参治疗预后评价  

Assessment of the long term role of Radix Salviae Miltiorrhizae in acute coronary syndrome

作　　者：邓中龙[1] 罗海明[1] 符德玉[1] 金露[1] 姚望[1] 姚春梅[1] 徐帮杰[1] 钱漪[1] 

机构地区：[1]上海中医药大学附属岳阳医院心内科,上海200437

出　　处：《中成药》2005年第6期682-685,共4页Chinese Traditional Patent Medicine

摘　　要：目的:观察丹参对急性冠脉综合征(acutecoronarysyndromeACS)的远期预后影响。方法:97例急性冠脉综合征患者分组对照治疗,治疗组加用丹参,观察临床疗效,治疗后纤维蛋白原(FIB)的变化,以及药物副作用。结果:治疗组心肌缺血改善更明显,心脏恶性事件下降;FIB浓度降低更明显。结论:在常规治疗的基础上,加用丹参可更好减少心脏事件发生;药物使用安全可靠。AIM:To investigate the effect of Radix Salviae Miltiorrhizae on the prognosis of patients with acute coronary syndrome(ACS). METHODS: 97 cases with ACS were randomly divided into a treatment group and a control group. The former was given Radix Salviae Miltiorrhizae and aspirin for about 1 year, the latter was treated with aspirin alone. Level of fibrinogen (FIB) was measured before and after treatment, Cardiovascular events and pharmacological side effects were monitored. RESULTS: The level of FIB was reduced more obviously in the former after therapy, ischemic events of cardiovascular disease were less in treatment group than in the control one. CONCLUSION:The treatment with Radix Salviae Miltiorrhizae and aspirin is more effective in treatment group than in the control, declining cardio-vascular events. The drug adverse reaction is mild, so, it is safe and beneficial to the prognosis of ACS patients.

关 键 词：急性冠脉综合征 丹参 纤维蛋白原 预后 

分 类 号：R287[医药卫生—中药学]